Tuesday, February 08, 2022 6:56:04 AM
Upcoming Milestones
Upcoming milestones
Adva-27a Drug Development Program:
>
GMP Manufacturing (5 Kilograms)
IND-Enabling Studies
Filing of IND Application ("Fast-Track" anticipated)
Phase I Clinical Trials (Pancreatic Cancer, Jewish General Hospital)
Antiviral Program:
Efficacy Studies in Coronavirus Infected Mice
.
GMP Manufacturing (5 Kilograms)
Filing of IND Application ("Fast-Track" anticipated)
Phase I Clinical Trials (University of Georgia Affiliate Hospital)
Upcoming milestones
Adva-27a Drug Development Program:
>
GMP Manufacturing (5 Kilograms)
IND-Enabling Studies
Filing of IND Application ("Fast-Track" anticipated)
Phase I Clinical Trials (Pancreatic Cancer, Jewish General Hospital)
Antiviral Program:
Efficacy Studies in Coronavirus Infected Mice
.
GMP Manufacturing (5 Kilograms)
Filing of IND Application ("Fast-Track" anticipated)
Phase I Clinical Trials (University of Georgia Affiliate Hospital)
Recent SBFM News
- Sunshine Biopharma Reports Fiscal 2025 Revenue of $36.3 Million, a 4.1% Increase Over Prior Year • ACCESS Newswire • 04/06/2026 12:30:00 PM
- Sunshine Biopharma Gains FDA-Equivalent Clearance in Canada for Domperidone to Treat Cancer-related Nausea • ACCESS Newswire • 10/28/2025 11:45:00 AM
- Sunshine Biopharma Launches STD, Acne and Lyme Disease Therapy Doxycycline • ACCESS Newswire • 10/20/2025 11:45:00 AM
- Sunshine Biopharma Launches Cholesterol Fighting Medicine Pravastatin • ACCESS Newswire • 10/16/2025 11:45:00 AM
- Sunshine Biopharma Allocates $5 Million for Investment in Bitcoin as Strategic Reserve Asset to Enhance Treasury Resilience • ACCESS Newswire • 10/14/2025 11:00:00 AM
- Sunshine Biopharma and University of Arizona Develop a Potent New Series of Protease Inhibitors for Treatment of SARS Coronavirus Infections • ACCESS Newswire • 10/09/2025 12:00:00 PM
